Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07948720
NA

Dexmedetomidine as an Adjuvant to Bupivacaine in Fascia Iliaca Block for Femoral Fracture Surgery Under General Anesthesia: A Dose-Finding Study

Sponsor: Cairo University

View on ClinicalTrials.gov

Summary

\### Brief Summary Femoral fractures can cause severe pain during and after surgery. Although fascia iliaca block is commonly used to relieve pain in patients undergoing femoral fracture surgery, the duration of pain relief may be limited. Dexmedetomidine is a medication that may prolong the pain-relieving effect of local anesthetics such as bupivacaine. However, the most appropriate dose of dexmedetomidine for this type of nerve block is not yet clearly established. This study aims to determine the lowest effective dose of dexmedetomidine when added to bupivacaine for ultrasound-guided fascia iliaca block in patients undergoing femoral fracture surgery under general anesthesia. The study includes 90 adult patients, aged 18-75 years, who are scheduled for femoral fracture surgery. Participants will be randomly assigned to one of three groups, with 30 patients in each group. All patients will receive general anesthesia and an ultrasound-guided fascia iliaca block containing 30 mL of 0.25% bupivacaine, combined with one of the following doses of dexmedetomidine: * Group A: 0.5 micrograms/kg. * Group B: 0.75 micrograms/kg. * Group C: 1 microgram/kg. Neither the patients nor the doctors assessing the study outcomes will know which dose has been administered. Pain levels will be assessed during the first 24 hours after surgery using a numerical pain scale. The study will also measure the time until patients first require additional pain medication and the total amount of pain medication used. Other assessments will include leg muscle strength, level of sedation, heart rate, blood pressure, and any possible side effects or complications. The main purpose of this study is to identify the lowest dose of dexmedetomidine that provides effective postoperative pain relief while minimizing unwanted effects, helping improve pain management and recovery after femoral fracture surgery.

Official title: Dexmedetomidine Added to Bupivacaine in Fascia Iliaca Block Combined With General Anesthesia for Femoral Fracture Surgery: A Dose-Finding Randomized Double-Blind Study

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2026-12-15

Completion Date

2027-04

Last Updated

2026-11-19

Healthy Volunteers

Yes

Interventions

DRUG

Dexmedetomidine 0.5 ug/kg

Intervention 1 - Group dexmeditomidine 0.5 Dexmedetomidine 0.5 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.5 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. \---

DRUG

Dexmedetomidine 0.75 mcg/kg

Name: Dexmedetomidine 0.75 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.75 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia.

DRUG

Dexmedetomidine 1 mcg/kg

Name: Dexmedetomidine 1 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 1 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia.